Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy
- 25 March 2005
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 56 (1), 91-96
- https://doi.org/10.1007/s00280-004-0924-9
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer: an EORTC phase II study (EORTC 08958)European Journal of Cancer, 2003
- Phase II trial combining paclitaxel with 24‐hour infusion cisplatin for chemotherapy‐naïve patients with locally advanced or metastatic breast carcinomaCancer, 2002
- Single-Dose Dexamethasone Paclitaxel PremedicationGynecologic Oncology, 1998
- Taxol Hypersensitivity: Rapid Retreatment Is Safe and Cost EffectiveGynecologic Oncology, 1998
- Phase II Study of 3-Hour Infusion of Paclitaxel in Patients with Previously Untreated Stage III and IV Non-Small Cell Lung CancerOncology, 1997
- Paclitaxel Premedication RegimensJNCI Journal of the National Cancer Institute, 1996
- Successful parenteral desensitization to paclitaxelJournal of Allergy and Clinical Immunology, 1996
- A Preliminary Risk-Benefit Assessment of PaclitaxelDrug Safety, 1995
- Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: A reviewClinical Oncology, 1994
- Histamine release in dogs by Cremophor El® and its derivatives: Oxethylated oleic acid is the most effective constituentInflammation Research, 1977